SEARCH

SEARCH BY CITATION

References

  • 1
    Whyte MP, Liberman UA. Rickets and osteomalacia (acquired and heritable forms) and skeletal dysplasias. In: Wass J, Stewart PM, editors. Oxford textbook of endocrinology and diabetes. 2nd ed. Vol. 1. New York: Oxford University Press; 2011. p. 7434.
  • 2
    Econs MJ, Drezner MK. Tumor-induced osteomalacia—unveiling a new hormone. N Engl J Med. 1994; 330(23): 167981.
  • 3
    White KE, Jonsson KB, Carn G, Hampson G, Spector TD, Mannstadt M, Lorenz-Depiereux B, Miyauchi A, Yang IM, Ljunggren O, Meitinger T, Strom TM, Juppner H, Econs MJ. The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. J Clin Endocrinol Metab. 2001; 86(2): 497500.
  • 4
    Jan DeBeur SM, Finnegan RB, Vassiliadis J, Cook B, Barberio D, Estes S, Manavalan P, Petroziello J, Madden SL, Cho JY, Kumar R, Levine MA, Schiavi SC. Tumors associated with oncogenic osteomalacia express genes important in bone and mineral metabolism. J Bone Miner Res. 2002; 17(6): 110210.
  • 5
    Ahn JM, Kim HJ, Cha CM, Kim J, Yim SG. Oncogenic osteomalacia: induced by tumor, cured by surgery. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007; 103(5): 63641.
  • 6
    Andreopoulou P, Dumitrescu CE, Kelly MH, Brillante BA, Peck CM, Wodajo FM, Chang R, Collins MT. Selective venous catheterization for the localization of phosphaturic mesenchymal tumors. J Bone Miner Res. 2011; 26(6): 1295302.
  • 7
    Bahrami A, Weiss SW, Montgomery E, Horvai AE, Jin L, Inwards CY, Folpe AL. RT-PCR analysis for FGF23 using paraffin sections in the diagnosis of phosphaturic mesenchymal tumors with and without known tumor induced osteomalacia. Am J Surg Pathol. 2009; 33(9): 134854.
  • 8
    Beech TJ, Rokade A, Gittoes N, Johnson AP. A haemangiopericytoma of the ethmoid sinus causing oncogenic osteomalacia: a case report and review of the literature. Int J Oral Maxillofac Surg. 2007; 36(10): 9568.
  • 9
    Casari S, Rossi V, Varenna M, Gasparini M, Parafioriti A, Failoni S, Sinigaglia L. A case of oncogenic osteomalacia detected by 111In-pentetreotide total body scan. Clin Exp Rheumatol. 2003; 21(4): 4936.
  • 10
    Cheung FM, Ma L, Wu WC, Siu TH, Choi PT, Tai YP. Oncogenic osteomalacia associated with an occult phosphaturic mesenchymal tumour: clinico-radiologico-pathological correlation and ultrastructural studies. Hong Kong Med J. 2006; 12(4): 31921.
  • 11
    Chouhan V, Agrawal K, Vinothkumar TK, Mathesul A. Bilateral insufficiency fracture of the femoral head and neck in a case of oncogenic osteomalacia. J Bone Joint Surg Br. 2010; 92(7): 102831.
  • 12
    Colt E, Gopan T, Chong HS. Oncogenic osteomalacia cured by removal of an organized hematoma. Endocr Pract. 2005; 11(3): 1903.
  • 13
    Dissanayake AM, Wilson JL, Holdaway IM, Reid IR. Oncogenic osteomalacia: culprit tumour detection whole body magnetic resonance imaging. Intern Med J. 2003; 33(12): 6156.
  • 14
    Duet M, Kerkeni S, Sfar R, Bazille C, Liote F, Orcel P. Clinical impact of somatostatin receptor scintigraphy in the management of tumor-induced osteomalacia. Clin Nucl Med. 2008; 33(11): 7526.
  • 15
    Dupond JL, Mahammedi H, Magy N, Blagosklonov O, Meaux-Ruault N, Kantelip B. Detection of a mesenchymal tumor responsible for hypophosphatemic osteomalacia using FDG-PET. Eur J Intern Med. 2005; 16(6): 4456.
  • 16
    Elston MS, Stewart IJ, Clifton-Bligh R, Conaglen JV. A case of oncogenic osteomalacia with preoperative secondary hyperparathyroidism: description of the biochemical response of FGF23 to octreotide therapy and surgery. Bone. 2007; 40(1): 23641.
  • 17
    Folpe AL, Fanburg-Smith JC, Billings SD, Bisceglia M, Bertoni F, Cho JY, Econs MJ, Inwards CY, Jan de Beur SM, Mentzel T, Montgomery E, Michal M, Miettinen M, Mills SE, Reith JD, O'Connell JX, Rosenberg AE, Rubin BP, Sweet DE, Vinh TN, Wold LE, Wehrli BM, White KE, Zaino RJ, Weiss SW. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol. 2004; 28(1): 130.
  • 18
    Fuentealba C, Pinto D, Ballesteros F, Pacheco D, Boettiger O, Soto N, Fernandez W, Gabler F, Gonzales G, Reginato AJ. Oncogenic hypophosphatemic osteomalacia associated with a nasal hemangiopericytoma. J Clin Rheumatol. 2003; 9(6): 3739.
  • 19
    Furco A, Roger M, Mouchet B, Richard O, Martinache X, Fur A. Osteomalacia cured by surgery. Eur J Intern Med. 2002; 13(1): 679.
  • 20
    Gascon A, Cobeta-Garcia JC, Iglesias E, Lazaro JM, Muniesa JA. Oncogenic osteomalacia in a patient with a fibrocystic nodule of the breast. Nephrol Dial Transplant. 1999; 14(6): 15613.
  • 21
    Gore MO, Welch BJ, Geng W, Kabbani W, Maalouf NM, Zerwekh JE, Moe OW, Sakhaee K. Renal phosphate wasting due to tumor-induced osteomalacia: a frequently delayed diagnosis. Kidney Int. 2009; 76(3): 3427.
  • 22
    Haeusler G, Freilinger M, Dominkus M, Egerbacher M, Amann G, Kolb A, Schlegel W, Raimann A, Staudenherz A. Tumor-induced hypophosphatemic rickets in an adolescent boy—clinical presentation, diagnosis, and histological findings in growth plate and muscle tissue. J Clin Endocrinol Metab. 2010; 95(10): 45117.
  • 23
    Halperin F, Anderson RJ, Mulder JE. Tumor-induced osteomalacia: the importance of measuring serum phosphorus levels. Nat Clin Pract Endocrinol Metab. 2007; 3(10): 7215.
  • 24
    Hannan FM, Athanasou NA, Teh J, Gibbons CL, Shine B, Thakker RV. Oncogenic hypophosphataemic osteomalacia: biomarker roles of fibroblast growth factor 23, 1,25-dihydroxyvitamin D3 and lymphatic vessel endothelial hyaluronan receptor 1. Eur J Endocrinol. 2008; 158(2): 26571.
  • 25
    Harbeck B, Schocklmann H, Seekamp A, Czech N, Monig H. Tumor-induced osteomalacia: successful treatment by radio-guided tumor surgery. J Clin Rheumatol. 2009; 15(1): 314.
  • 26
    Harish S, Jurriaans E, Jan E, Sur M, Colterjohn N. Giant cell tumour of soft tissue causing oncogenic osteomalacia: report demonstrating the use of octreotide scintigraphy in tumour localization. Clin Radiol. 2008; 63(1): 1017.
  • 27
    Hesse E, Moessinger E, Rosenthal H, Laenger F, Brabant G, Petrich T, Gratz KF, Bastian L. Oncogenic osteomalacia: exact tumor localization by co-registration of positron emission and computed tomography. J Bone Miner Res. 2007; 22(1): 15862.
  • 28
    Hoogendoorn EH, White KE, Econs MJ, Hermus AR. Hypophosphatemia, osteomalacia and proximal muscle weakness treated by surgery. Clin Endocrinol (Oxf). 2003; 58(6): 7967.
  • 29
    Inokuchi G, Tanimoto H, Ishida H, Sugimoto T, Yamauchi M, Miyauchi A, Nibu K. A paranasal tumor associated with tumor-induced osteomalacia. Laryngoscope. 2006; 116(10): 19303.
  • 30
    Ishii A, Imanishi Y, Kobayashi K, Hashimoto J, Ueda T, Miyauchi A, Koyano HM, Kaji H, Saito T, Oba K, Komatsu Y, Kurajoh M, Nagata Y, Goto H, Wakasa K, Sugimoto T, Miki T, Inaba M, Nishizawa Y. The levels of somatostatin receptors in causative tumors of oncogenic osteomalacia are insufficient for their agonist to normalize serum phosphate levels. Calcif Tissue Int. 2010; 86(6): 45562.
  • 31
    Ito N, Shimizu Y, Suzuki H, Saito T, Okamoto T, Hori M, Akahane M, Fukumoto S, Fujita T. Clinical utility of systemic venous sampling of FGF23 for identifying tumours responsible for tumour-induced osteomalacia. J Intern Med. 2010; 268(4): 3904.
  • 32
    Jacob JJ, Finny P, Thomas M, Thomas N, John M. Oncogenic osteomalacia. J Assoc Physicians India. 2007; 55: 2313.
  • 33
    Jan de Beur SM, Streeten EA, Civelek AC, McCarthy EF, Uribe L, Marx SJ, Onobrakpeya O, Raisz LG, Watts NB, Sharon M, Levine MA. Localisation of mesenchymal tumours by somatostatin receptor imaging. Lancet. 2002; 359(9308): 7613.
  • 34
    Jung GH, Kim JD, Cho Y, Chung SH, Lee JH, Sohn KR. A 9-month-old phosphaturic mesenchymal tumor mimicking the intractable rickets. J Pediatr Orthop B. 2010; 19(1): 12732.
  • 35
    Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Juppner H. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med. 2003; 348(17): 165663.
  • 36
    Kaul M, Silverberg M, Dicarlo EF, Schneider R, Bass AR, Erkan D. Tumor-induced osteomalacia. Clin Rheumatol. 2007; 26(9): 15759.
  • 37
    Kaylie DM, Jackson CG, Gardner EK. Oncogenic osteomalacia caused by phosphaturic mesenchymal tumor of the temporal bone. Otolaryngol Head Neck Surg. 2006; 135(4): 6534.
  • 38
    Kenealy H, Holdaway I, Grey A. Occult nasal sinus tumours causing oncogenic osteomalacia. Eur J Intern Med. 2008; 19(7): 5169.
  • 39
    Khosravi A, Cutler CM, Kelly MH, Chang R, Royal RE, Sherry RM, Wodajo FM, Fedarko NS, Collins MT. Determination of the elimination half-life of fibroblast growth factor-23. J Clin Endocrinol Metab. 2007; 92(6): 23747.
  • 40
    Kim YG, Choi YS, Lee SC, Ryu DM. Tumor-induced osteomalacia associated with lesions in the oral and maxillofacial region: report of two cases. J Oral Maxillofac Surg. 1996; 54(11): 13527.
  • 41
    Kimizuka T, Ozaki Y, Sumi Y. Usefulness of 201Tl and 99mTc MIBI scintigraphy in a case of oncogenic osteomalacia. Ann Nucl Med. 2004; 18(1): 637.
  • 42
    Kobayashi K, Nakao K, Kawai K, Ito K, Hukumoto S, Asakage T, Oota S, Motoi R. Tumor-induced osteomalacia originating from the temporal bone: a case report. Head Neck. 2011; 33(7): 10725.
  • 43
    Koriyama N, Nishimoto K, Kodama T, Nakazaki M, Kurono Y, Yoshida H, Tei C. Oncogenic osteomalacia in a case with a maxillary sinus mesenchymal tumor. Am J Med Sci. 2006; 332(3): 1427.
  • 44
    Kurien R, Manipadam MT, Rupa V. Oncogenic osteomalacia in a patient with an ethmoid sinus tumour. J Laryngol Otol. 2010; 124(7): 799803.
  • 45
    Ladha SS, Whitaker MD, Bosch EP. Oncogenic osteomalacia: muscular weakness and multiple fractures. Neurology. 2006; 67(2): 3645.
  • 46
    Lamont EB, Cavaghan MK, Brockstein BE. Oncogenic osteomalacia as a harbinger of recurrent osteosarcoma. Sarcoma. 1999; 3(2): 959.
  • 47
    Lee DY, Choi IH, Lee CK, Chung CY, Cho KH. Acquired vitamin D-resistant rickets caused by aggressive osteoblastoma in the pelvis: a case report with ten years' follow-up and review of the literature. J Pediatr Orthop. 1994; 14(6): 7938.
  • 48
    Lewiecki EM, Urig EJ Jr, Williams RC Jr. Tumor-induced osteomalacia: lessons learned. Arthritis Rheum. 2008; 58(3): 7737.
  • 49
    Lui CY, Khoo R, Law TC, Chong SF. Case report. Tumour-induced osteomalacia in a patient with osseous haemangioma. Clin Radiol. 2002; 57(12): 11257.
  • 50
    Mannstadt M, Lorente C, Juppner H. Rapid detection of intact FGF-23 in tumor tissue from patients with oncogenic osteomalacia. Clin Chem. 2008; 54(7): 12524.
  • 51
    Mekinian A, Ladsous M, Balavoine AS, Carnaille B, Aubert S, Soudan B, Wemeau JL. Curative surgical treatment after inefficient long-acting somatostatin analogues therapy of a tumor-induced osteomalacia. Presse Med. 2011; 40(3): 30913.
  • 52
    Mori Y, Ogasawara T, Motoi T, Shimizu Y, Chikazu D, Tamura K, Fukumoto S, Takato T. Tumor-induced osteomalacia associated with a maxillofacial tumor producing fibroblast growth factor 23: report of a case and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010; 109(3): e5763.
  • 53
    Mussig K, Oksuz MO, Pfannenberg C, Adam P, Zustin J, Beckert S, Petersenn S. Somatostatin receptor expression in an epitheloid hemangioma causing oncogenic osteomalacia. J Clin Endocrinol Metab. 2009; 94(11): 41234.
  • 54
    Nasu T, Kurisu S, Matsuno S, Tatsumi K, Kakimoto T, Kobayashi M, Nakano Y, Wakasaki H, Furuta H, Nishi M, Sasaki H, Suzuki H, Ito N, Fukumoto S, Nanjo K. Tumor-induced hypophosphatemic osteomalacia diagnosed by the combinatory procedures of magnetic resonance imaging and venous sampling for FGF23. Intern Med. 2008; 47(10): 95761.
  • 55
    Nawrot-Wawrzyniak K, Varga F, Nader A, Roschger P, Sieghart S, Zwettler E, Roetzer KM, Lang S, Weinkamer R, Klaushofer K, Fratzl-Zelman N. Effects of tumor-induced osteomalacia on the bone mineralization process. Calcif Tissue Int. 2009; 84(4): 31323.
  • 56
    Nelson AE, Bligh RC, Mirams M, Gill A, Au A, Clarkson A, Juppner H, Ruff S, Stalley P, Scolyer RA, Robinson BG, Mason RS, Bligh PC. Clinical case seminar: fibroblast growth factor 23: a new clinical marker for oncogenic osteomalacia. J Clin Endocrinol Metab. 2003; 88(9): 408894.
  • 57
    Nguyen BD, Wang EA. Indium-111 pentetreotide scintigraphy of mesenchymal tumor with oncogenic osteomalacia. Clin Nucl Med. 1999; 24(2): 1301.
  • 58
    Ogura E, Kageyama K, Fukumoto S, Yagihashi N, Fukuda Y, Kikuchi T, Masuda M, Suda T. Development of tumor-induced osteomalacia in a subcutaneous tumor, defined by venous blood sampling of fibroblast growth factor-23. Intern Med. 2008; 47(7): 63741.
  • 59
    Oka M, Kamo T, Sasaki E, Kaji H, Nishizawa H, Imanishi Y, Nishigori C. A case of phosphaturic mesenchymal tumour (mixed connective tissue variant) that developed in the subcutaneous tissue of a patient with oncogenic osteomalacia and produced fibroblast growth factor 23. Br J Dermatol. 2007; 157(1): 198200.
  • 60
    Park YK, Unni KK, Beabout JW, Hodgson SF. Oncogenic osteomalacia: a clinicopathologic study of 17 bone lesions. J Korean Med Sci. 1994; 9(4): 28998.
  • 61
    Pedrazzoli M, Colletti G, Ferrari M, Rossetti G, Moneghini L, Autelitano L. Mesenchymal phosphaturic neoplasm in the maxillary sinus: a case report. Int J Oral Maxillofac Surg. 2010; 39(10): 102732.
  • 62
    Peters KB, McLendon R, Morse MA, Vredenburgh JJ. Treatment of recurrent intracranial hemangiopericytoma with SRC-related tyrosine kinase targeted therapy: a case report. Case Rep Oncol. 2010; 3(1): 937.
  • 63
    Peterson NR, Summerlin DJ, Cordes SR. Multiple phosphaturic mesenchymal tumors associated with oncogenic osteomalacia: case report and review of the literature. Ear Nose Throat J. 2010; 89(6): E115.
  • 64
    Pirola E, Vergani F, Casiraghi P, Leone EB, Guerra P, Sganzerla EP. Oncogenic osteomalacia caused by a phosphaturic mesenchymal tumor of the thoracic spine. J Neurosurg Spine. 2009; 10(4): 32933.
  • 65
    Policarpio-Nicolas ML, Abbott TE, Dalkin AC, Bennett-Wick J, Frierson HF Jr. Phosphaturic mesenchymal tumor diagnosed by fine-needle aspiration and core biopsy: a case report and review of literature. Diagn Cytopathol. 2008; 36(2): 1159.
  • 66
    Radaideh AR, Jaradat D, Abu-Kalaf MM, Nusier MK. Resolution of severe oncogenic hypophosphatemic osteomalacia after resection of a deeply located soft-tissue tumour. Curr Oncol. 2009; 16(5): 8790.
  • 67
    Ratanasuwan T, Chetsurakarn S, Ongphiphadhanakul B, Damrongkitchaiporn S. A case report of tumor-induced osteomalacia: eight year followed-up. J Med Assoc Thai. 2008; 91(12): 19002.
  • 68
    Rendina D, De Filippo G, Tauchmanova L, Insabato L, Muscariello R, Gianfrancesco F, Esposito T, Cioffi M, Colao A, Strazzullo P, Mossetti G. Bone turnover and the osteoprotegerin-RANKL pathway in tumor-induced osteomalacia: a longitudinal study of five cases. Calcif Tissue Int. 2009; 85(4): 293300.
  • 69
    Roarke MC, Nguyen BD. PET/CT localization of phosphaturic mesenchymal neoplasm causing tumor-induced osteomalacia. Clin Nucl Med. 2007; 32(4): 3001.
  • 70
    Romualdo-Silva DD, Silva BC, Caetano CV, Tiburcio AM, Nunes MB, Chagas SA, Polito ET, Ferreira AR, Purisch S. Tumor-induced osteomalacia: a case report. Arq Bras Endocrinol Metabol. 2009; 53(3): 37882.
  • 71
    Sahnoune I, Tazi-Mezalek Z, Essaadouni L, Harmouche H, Ismael F, Adnaoui M, Aouni M, Kettani F, Maaouni A. Oncogenic osteomalacia in a patient with hemangioma: a clinical diagnosis. Joint Bone Spine. 2006; 73(1): 1158.
  • 72
    Sato K, Obara T, Yamazaki K, Kanbe M, Nakajima K, Yamada A, Yanagisawa T, Kato Y, Nishikawa T, Takano K. Somatic mutations of the MEN1 gene and microsatellite instability in a case of tertiary hyperparathyroidism occurring during high phosphate therapy for acquired, hypophosphatemic osteomalacia. J Clin Endocrinol Metab. 2001; 86(11): 556471.
  • 73
    Savage CR, Zimmer LA. Oncogenic osteomalacia from pterygopalatine fossa mass. J Laryngol Otol. 2009; 123(9): 10524.
  • 74
    Seijas R, Ares O, Sierra J, Perez-Dominguez M. Oncogenic osteomalacia: two case reports with surprisingly different outcomes. Arch Orthop Trauma Surg. 2009; 129(4): 5339.
  • 75
    Shane E, Parisien M, Henderson JE, Dempster DW, Feldman F, Hardy MA, Tohme JF, Karaplis AC, Clemens TL. Tumor-induced osteomalacia: clinical and basic studies. J Bone Miner Res. 1997; 12(9): 150211.
  • 76
    Shulman DI, Hahn G, Benator R, Washington K, White KE, Farber J, Econs MJ. Tumor-induced rickets: usefulness of MR gradient echo recall imaging for tumor localization. J Pediatr. 2004; 144(3): 3815.
  • 77
    Siris ES, Clemens TL, Dempster DW, Shane E, Segre GV, Lindsay R, Bilezikian JP. Tumor-induced osteomalacia. Kinetics of calcium, phosphorus, and vitamin D metabolism and characteristics of bone histomorphometry. Am J Med. 1987; 82(2): 30712.
  • 78
    Takeuchi Y, Suzuki H, Ogura S, Imai R, Yamazaki Y, Yamashita T, Miyamoto Y, Okazaki H, Nakamura K, Nakahara K, Fukumoto S, Fujita T. Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia. J Clin Endocrinol Metab. 2004; 89(8): 397982.
  • 79
    Tartaglia F, Minisola S, Sgueglia M, Blasi S, Brunelli D, Degli Effetti E, Maturo A, Cola A, Custureri F, Campana FP. Tumor-induced hypophosphatemic osteomalacia associated with tertiary hyperparathyroidism: a case report. G Chir. 2006; 27(1–2): 913.
  • 80
    Teasell RW, Shapiro AP. Misdiagnosis of conversion disorders. Am J Phys Med Rehabil. 2002; 81(3): 23640.
  • 81
    Toyosawa S, Tomita Y, Kishino M, Hashimoto J, Ueda T, Tsujimura T, Aozasa K, Ijuhin N, Komori T. Expression of dentin matrix protein 1 in tumors causing oncogenic osteomalacia. Mod Pathol. 2004; 17(5): 5738.
  • 82
    Ungari C, Rocchi G, Rinna C, Agrillo A, Lattanzi A, Pagnoni M. Hypophosphaturic mesenchymal tumor of the ethmoid associated with oncogenic osteomalacia. J Craniofac Surg. 2004; 15(3): 5237.
  • 83
    Uramoto N, Furukawa M, Yoshizaki T. Malignant phosphaturic mesenchymal tumor, mixed connective tissue variant of the tongue. Auris Nasus Larynx. 2009; 36(1): 1045.
  • 84
    van Boekel G, Ruinemans-Koerts J, Joosten F, Dijkhuizen P, van Sorge A, de Boer H. Tumor producing fibroblast growth factor 23 localized by two-staged venous sampling. Eur J Endocrinol. 2008; 158(3): 4317.
  • 85
    Vandergheynst F, Van Dorpe J, Goldman S, Decaux G. Increased 18F fluorodeoxyglucose uptake of a vertebral hemangioma responsible for oncogenic osteomalacia. Eur J Intern Med. 2006; 17(3): 223.
  • 86
    Vollbrecht JE, Rao DS. Images in clinical medicine. Tumor-induced osteomalacia. N Engl J Med. 2008; 358(12): 1282.
  • 87
    Ward LM, Rauch F, White KE, Filler G, Matzinger MA, Letts M, Travers R, Econs MJ, Glorieux FH. Resolution of severe, adolescent-onset hypophosphatemic rickets following resection of an FGF-23-producing tumour of the distal ulna. Bone. 2004; 34(5): 90511.
  • 88
    Woo VL, Landesberg R, Imel EA, Singer SR, Folpe AL, Econs MJ, Kim T, Harik LR, Jacobs TP. Phosphaturic mesenchymal tumor, mixed connective tissue variant, of the mandible: report of a case and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009; 108(6): 92532.
  • 89
    Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T, Fukumoto S. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab. 2002; 87(11): 495760.
  • 90
    Yoshioka K, Nagata R, Ueda M, Yamaguchi T, Konishi Y, Hosoi M, Inoue T, Yamanaka K, Iwai Y, Sato T. Phosphaturic mesenchymal tumor with symptoms related to osteomalacia that appeared one year after tumorectomy. Intern Med. 2006; 45(20): 115760.
  • 91
    Zimering MB, Caldarella FA, White KE, Econs MJ. Persistent tumor-induced osteomalacia confirmed by elevated postoperative levels of serum fibroblast growth factor-23 and 5-year follow-up of bone density changes. Endocr Pract. 2005; 11(2): 10814.
  • 92
    Hesse E, Rosenthal H, Bastian L. Radiofrequency ablation of a tumor causing oncogenic osteomalacia. N Engl J Med. 2007; 357(4): 4224.
  • 93
    Khadgawat R, Singh Y, Kansara S, Tandon N, Bal C, Seith A, Kotwal P. PET/CT localisation of a scapular haemangiopericytoma with tumour-induced osteomalacia. Singapore Med J. 2009; 50(2): e557.
  • 94
    Lee HK, Sung WW, Solodnik P, Shimshi M. Bone scan in tumor-induced osteomalacia. J Nucl Med. 1995; 36(2): 2479.
  • 95
    Auethavekiat P, Roberts JR, Biega TJ, Toney MO, Christensen RS, Belnap CM, Berenberg JL. Case 3. Oncogenic osteomalacia associated with hemangiopericytoma localized by octreotide scan. J Clin Oncol. 2005; 23(15): 36268.
  • 96
    Gershinsky M, Croitoru S, Dickstein G, Bardicef O, Gelman R, Barmeir E. Imaging of oncogenic osteomalacia. Isr Med Assoc J. 2007; 9(7): 5667.
  • 97
    Marshall AE, Martin SE, Agaram NP, Chen JH, Horn EM, Douglas-Akinwande AC, Hattab EM. A 61-year-old woman with osteomalacia and a thoracic spine lesion. Brain Pathol. 2010; 20(2): 499502.
  • 98
    Dupond JL, Mahammedi H, Prie D, Collin F, Gil H, Blagosklonov O, Ricbourg B, Meaux-Ruault N, Kantelip B. Oncogenic osteomalacia: diagnostic importance of fibroblast growth factor 23 and F-18 fluorodeoxyglucose PET/CT scan for the diagnosis and follow-up in one case. Bone. 2005; 36(3): 3758.
  • 99
    Farrow EG, White KE. Tumor-induced osteomalacia. Expert Rev Endocrinol Metab. 2009; 4(5): 43542.
  • 100
    Ryan EA, Reiss E. Oncogenous osteomalacia. Review of the world literature of 42 cases and report of two new cases. Am J Med. 1984; 77(3): 50112.
  • 101
    Xia WB, Jiang Y, Li M, Xing XP, Wang O, Hu YY, Zhang HB, Liu HC, Meng XW, Zhou XY. Levels and dynamic changes of serum fibroblast growth factor 23 in hypophosphatemic rickets/osteomalacia. Chin Med J (Engl). 2010; 123(9): 115862.
  • 102
    Walton RJ, Bijvoet OL. Nomogram for derivation of renal threshold phosphate concentration. Lancet. 1975; 2(7929): 30910.
  • 103
    Xia W, Meng X, Jiang Y, Li M, Xing X, Pang L, Wang O, Pei Y, Yu LY, Sun Y, Hu Y, Zhou X. Three novel mutations of the PHEX gene in three Chinese families with X-linked dominant hypophosphatemic rickets. Calcif Tissue Int. 2007; 81(6): 41520.
  • 104
    Chong WH, Molinolo AA, Chen CC, Collins MT. Tumor-induced osteomalacia. Endocr Relat Cancer. 2011; 18(3): R5377.
  • 105
    Weidner N, Santa Cruz D. Phosphaturic mesenchymal tumors. A polymorphous group causing osteomalacia or rickets. Cancer. 1987; 59(8): 144254.
  • 106
    Brame LA, White KE, Econs MJ. Renal phosphate wasting disorders: clinical features and pathogenesis. Semin Nephrol. 2004; 24(1): 3947.
  • 107
    Firth RG, Grant CS, Riggs BL. Development of hypercalcemic hyperparathyroidism after long-term phosphate supplementation in hypophosphatemic osteomalacia. Report of two cases. Am J Med. 1985; 78(4): 66973.
  • 108
    Rhee Y, Lee JD, Shin KH, Lee HC, Huh KB, Lim SK. Oncogenic osteomalacia associated with mesenchymal tumour detected by indium-111 octreotide scintigraphy. Clin Endocrinol (Oxf). 2001; 54(4): 5514.
  • 109
    Seufert J, Ebert K, Muller J, Eulert J, Hendrich C, Werner E, Schuuze N, Schulz G, Kenn W, Richtmann H, Palitzsch KD, Jakob F. Octreotide therapy for tumor-induced osteomalacia. N Engl J Med. 2001; 345(26): 18838.
  • 110
    Sato K, Nohtomi K, Demura H, Takeuchi A, Kobayashi T, Kazama J, Ozawa H. Saccharated ferric oxide (SFO)-induced osteomalacia: in vitro inhibition by SFO of bone formation and 1,25-dihydroxy-vitamin D production in renal tubules. Bone. 1997; 21(1): 5764.
  • 111
    Schouten BJ, Doogue MP, Soule SG, Hunt PJ. Iron polymaltose-induced FGF23 elevation complicated by hypophosphataemic osteomalacia. Ann Clin Biochem. 2009; 46(Pt 2): 1679.
  • 112
    Shimizu Y, Tada Y, Yamauchi M, Okamoto T, Suzuki H, Ito N, Fukumoto S, Sugimoto T, Fujita T. Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia. Bone. 2009; 45(4): 8146.
  • 113
    Schouten BJ, Hunt PJ, Livesey JH, Frampton CM, Soule SG. FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study. J Clin Endocrinol Metab. 2009; 94(7): 23327.
  • 114
    Imel EA, Peacock M, Gray AK, Padgett LR, Hui SL, Econs MJ. Iron Modifies Plasma FGF23 Differently in Autosomal Dominant Hypophosphatemic Rickets and Healthy Humans. J Clin Endocrinol Metab. 2011; 96(11): 35419.
  • 115
    Farrow EG, Yu X, Summers LJ, Davis SI, Fleet JC, Allen MR, Robling AG, Stayrook KR, Jideonwo V, Magers MJ, Garringer HJ, Vidal R, Chan RJ, Goodwin CB, Hui SL, Peacock M, White KE. Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci U S A. 2011 Nov 15; 108(46): E114655.